Anandron

Known as: Aventis Brand of Nilutamide, Hoechst Brand of Nilutamide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2004
0246819752004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Medroxyprogesterone acetate (MPA), which is frequently used as second line hormonal therapy for the treatment of metastatic… (More)
Is this relevant?
1998
1998
PURPOSE The aim of the study was to evaluate the efficacy of antiandrogen therapy on overall survival and response in… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Although the majority of primary human breast cancers express the androgen receptor (AR), the role of androgens in breast cancer… (More)
Is this relevant?
1994
1994
The role of androgens and the androgen receptor (AR) in the development and progression of breast cancer is poorly understood. To… (More)
Is this relevant?
1991
1991
Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using… (More)
Is this relevant?
1991
1991
Androgen receptors are present in 30-50% of primary breast carcinomas (Bretani et al., 1986; Miller et al., 1985; Bryan et al… (More)
  • table I
  • table II
Is this relevant?
1990
1990
A randomized double-blind study with a 3-yr follow-up comparing the two arms "orchiectomy + Anandron (300 mg)" vs "orchiectomy… (More)
Is this relevant?
1990
1990
The effect of Anandron, a nonsteroidal antiandrogen, on the reproductive system and fertility of adult male rats was studied… (More)
Is this relevant?
1986
1986
Approximately 65% of patients with prostatic cancer treated by the combination therapy using a gonadorelin (LHRH) agonist or… (More)
  • figure 1
  • table I
Is this relevant?
1986
1986
To improve the inhibition of prostate cancer growth obtained by surgical or chemical castration (estrogens or LHRH analogs… (More)
Is this relevant?